The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors.
Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer (CRPC).
Written by:
Bitting RL, Armstrong AJ. Are you the author?
R Bitting, Medicine/Oncology, Duke University, Durham, 27710, United States.
Reference: Endocr Relat Cancer. 2013 Mar 1. Epub ahead of print.
doi: 10.1530/ERC-12-0394
PubMed Abstract
PMID: 23456430
UroToday.com Investigative Urology Section
